{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-013368","form_type":"8-K","ticker":"KAPA","cik":"0001962011","company_name":"Kairos Pharma, LTD.","filed_at":"2025-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.581367+00:00","generated_at":"2026-05-20T02:01:04.501100+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kairos Pharma presents KROS101 preclinical data at ASCO; shows superiority over TRX518","bullets":["KROS101 is a small molecule GITR ligand agonist with dual mechanisms: promotes T effector proliferation and reduces T reg suppression.","Preclinical study showed KROS101 enhanced T cell cytotoxicity and cytokine production, boosting tumor cell killing.","KROS101 was superior to anti-GITR antibody TRX518 in T cell tumor infiltration, T reg reduction, and preventing T cell exhaustion.","CEO Dr. John Yu presented findings at ASCO 2025 (May 30-June 3) and expressed strong support for continued study of KROS101."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-013368","json":"https://secwatch.observer/filing/0001641172-25-013368.json","markdown":"https://secwatch.observer/filing/0001641172-25-013368.md","text":"https://secwatch.observer/filing/0001641172-25-013368.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1962011/000164117225013368/0001641172-25-013368-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1962011/000164117225013368/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T02:01:04.501100+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}